MedPath
Found 1 clinical trials|View Analysis
Sort by:

Tumor Treating Fields for Locally Advanced NSCLC

Phase 1
Recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Device: NovoTTF-200T (TTFields) System
Radiation: carboplatin chemotherapy
Drug: Durvalumab
First Posted Date
2023-11-09
Last Posted Date
2024-10-07
Lead Sponsor
University of Utah
Target Recruit Count
30
Registration Number
NCT06124118
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath